Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

911 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients.
Maillard A, Redjoul R, Klemencie M, Labussière Wallet H, Le Bourgeois A, D'Aveni M, Huynh A, Berceanu A, Marchand T, Chantepie S, Botella Garcia C, Loschi M, Joris M, Castilla-Llorente C, Thiebaut-Bertrand A, François S, Leclerc M, Chevallier P, Nguyen S. Maillard A, et al. Among authors: chevallier p. Blood. 2022 Jan 6;139(1):134-137. doi: 10.1182/blood.2021014232. Blood. 2022. PMID: 34818411 Free PMC article. No abstract available.
Impact of cyclosporine-A concentration on the incidence of severe acute graft-versus-host disease after allogeneic stem cell transplantation.
Malard F, Szydlo RM, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Saulquin B, Harousseau JL, Moreau P, Mohty M. Malard F, et al. Among authors: chevallier p. Biol Blood Marrow Transplant. 2010 Jan;16(1):28-34. doi: 10.1016/j.bbmt.2009.08.010. Epub 2009 Oct 1. Biol Blood Marrow Transplant. 2010. PMID: 20053329 Free article.
Fludarabine, antithymocyte globulin, and very low-dose busulfan for reduced-intensity conditioning before allogeneic stem cell transplantation in patients with lymphoid malignancies.
Malard F, Cahu X, Clavert A, Brissot E, Chevallier P, Guillaume T, Delaunay J, Ayari S, Dubruille V, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Miplied N, Le Gouill S, Mohty M. Malard F, et al. Among authors: chevallier p. Biol Blood Marrow Transplant. 2011 Nov;17(11):1698-703. doi: 10.1016/j.bbmt.2011.04.010. Epub 2011 May 3. Biol Blood Marrow Transplant. 2011. PMID: 21601642 Free article.
Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC.
Chevallier P, Szydlo RM, Blaise D, Tabrizi R, Michallet M, Uzunov M, Fegueux N, Guilhot F, Lapusan S, Gratecos N, Cahn JY, Socié G, Yakoub-Agha I, Huynh A, Francois S, Bay JO, Maury S, Buzyn A, Contentin N, Mohty M. Chevallier P, et al. Biol Blood Marrow Transplant. 2012 Feb;18(2):289-94. doi: 10.1016/j.bbmt.2011.07.013. Epub 2011 Jul 23. Biol Blood Marrow Transplant. 2012. PMID: 21781949 Free article. Clinical Trial.
Early matched sibling hematopoietic cell transplantation for adult AML in first remission using an age-adapted strategy: long-term results of a prospective GOELAMS study.
Lioure B, Béné MC, Pigneux A, Huynh A, Chevallier P, Fegueux N, Blaise D, Witz B, Delain M, Cornillon J, Luquet I, Blanchet O, Cornillet-Lefebvre P, Carré M, Hunault M, Larosa F, Lamy T, Randriamalala E, Ojeda-Uribe M, Berthou C, Fornecker L, Harousseau JL, Bouscary D, Ifrah N, Cahn JY; GOELAMS. Lioure B, et al. Among authors: chevallier p. Blood. 2012 Mar 22;119(12):2943-8. doi: 10.1182/blood-2011-05-352989. Epub 2012 Feb 9. Blood. 2012. PMID: 22323482 Free article. Clinical Trial.
Azacitidine after allo-SCT: the good without the bad?
Mohty M, Chevallier P. Mohty M, et al. Among authors: chevallier p. Blood. 2012 Apr 5;119(14):3199-200. doi: 10.1182/blood-2012-02-406678. Blood. 2012. PMID: 22493216 Free article. No abstract available.
Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).
Le Bourgeois A, Lestang E, Guillaume T, Delaunay J, Ayari S, Blin N, Clavert A, Tessoulin B, Dubruille V, Mahe B, Roland V, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Chevallier P. Le Bourgeois A, et al. Among authors: chevallier p. Eur J Haematol. 2013 Mar;90(3):177-86. doi: 10.1111/ejh.12049. Epub 2013 Jan 27. Eur J Haematol. 2013. PMID: 23301689
Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.
Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P. Le Bourgeois A, et al. Among authors: chevallier p. Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21. Biol Blood Marrow Transplant. 2013. PMID: 23523970 Free article.
911 results